Zobrazeno 1 - 10
of 476
pro vyhledávání: ''
Autor:
Andrea Ferrari, Daniel Orbach, Monika Sparber-Sauer, David O. Walterhouse, Kristian W. Pajtler, William H. Meyer, Sheri L. Spunt, Aaron R. Weiss
Publikováno v:
European journal of cancer (Oxford, England : 1990). 169
The current article focuses on non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), the heterogeneous group of mesenchymal tumours different from rhabdomyosarcoma that may affect children and adolescents, with clinical behaviour varying from relatively
Autor:
Simone Hettmer, Corinne M. Linardic, Anna Kelsey, Erin R. Rudzinski, Christian Vokuhl, Joanna Selfe, Olivia Ruhen, Jack F. Shern, Javed Khan, Alexander R. Kovach, Philip J. Lupo, Susanne A. Gatz, Beat W. Schäfer, Samuel Volchenboum, Véronique Minard-Colin, Ewa Koscielniak, Douglas S. Hawkins, Gianni Bisogno, Monika Sparber-Sauer, Rajkumar Venkatramani, Johannes H.M. Merks, Janet Shipley
Publikováno v:
European journal of cancer (Oxford, England : 1990). 172
Rhabdomyosarcomas (RMSs) are the most common soft tissue sarcomas in children/adolescents less than 18 years of age with an annual incidence of 1-2/million. Inter/intra-tumour heterogeneity raise challenges in clinical, pathological and biological re
Autor:
Axel Budde, Katja Baust, Leonie Weinhold, Mark Bernstein, Stefan Bielack, Catharina Dhooge, Lars Hjorth, Katherine A. Janeway, Meriel Jenney, Mark D. Krailo, Neyssa Marina, Rajaram Nagarajan, Sigbjørn Smeland, Matthew R. Sydes, Patricia De Vos, Jeremy Whelan, Andreas Wiener, Gabriele Calaminus, Matthias Schmid
Publikováno v:
EUROPEAN JOURNAL OF CANCER
Purpose: The available questionnaires for quality-of-life (QoL) assessments are age-group specific, limiting comparability and impeding longitudinal analyses. The comparability of measurements, however, is a necessary condition for gaining scientific
Autor:
Maximilian Gassenmaier, Narges Soltanpour, Laura Held, Gisela Metzler, Amir S. Yazdi, Ines B. Brecht, Dominik T. Schneider, Rudolf Stadler, Claus Garbe, Jürgen Bauer
Publikováno v:
European journal of cancer (Oxford, England : 1990). 163
Histological classification of atypical spitzoid tumours (ASTs) is unreliable, and categorisation of these lesions into benign and malignant is poorly reproducible. Here, we classified ASTs based on histology and chromosomal aberrations and explored
Autor:
Pan Wang, Qiu-Yan Chen, Dong-Xiang Wen, Yu-Jing Liang, Shan-Shan Guo, Mei-Juan Luo, Li-Ting Liu, Lin-Quan Tang, Hai-Qiang Mai
Publikováno v:
European journal of cancer (Oxford, England : 1990). 159
To compare the prognosis and adverse effects of induction or adjuvant chemotherapy (IC or AC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in paediatric nasopharyngeal carcinoma (NPC) patients in the intensity-modulated radiotherapy (IM
Publikováno v:
European Journal of Cancer
Background Efficacy and safety data of COVID-19 vaccines among cancer populations have been limited; however, preliminary data from recent studies have emerged regarding their immunogenicity and safety in this population. In this review, we examined
Autor:
Kirsten B. Goldberg, Thomas U. Marron, Yutao Gong, Chieh J. Lee, Celina Ang, Pallavi S. Mishra-Kalyani, Tiziana Pressiani, Thoetchai Peeraphatdit, Lola Fashoyin-Aje, Anushi Bulumulle, Elad Sharon, Mahvish Muzaffar, Alessio Cortellini, Pei Chang Lee, Ahmed Kaseb, David J. Pinato, Steven Lemery, Uqba Khan, Anwaar Saeed, Sonal Paul, Yinghong Wang, Yehia I. Abugabal, Bo Yu, Tomi Jun, Sirish Dharmapuri, Nicola Personeni, Lorenza Rimassa, Antonio D'Alessio, Guo Wei, Marc R. Theoret, Musharraf Navaid, Anuhya Gampa, Richard Pazdur, Hannah Hildebrand, Abdul Rafeh Naqash, Neil Nimkar, Yi Hsiang Huang, David Szafron, Julie A. Schneider, Lorraine Pelosof, Dominik Bettinger, Anjana Pillai
Publikováno v:
European journal of cancer (Oxford, England : 1990). 157
Purpose The development of treatment-related adverse events (trAE) correlates favorably with clinical outcomes in multiple studies of patients receiving immune checkpoint inhibitors (ICI); however, this relationship is undefined in patients with hepa
Autor:
Tadeusz Dyba, M Bettio, Francesco Giusti, Giorgia Randi, Freddie Bray, Luciana Neamtiu, M. Flego, Jacques Ferlay, Anna Gavin, Nadya Dimitrova, N. Nicholson, Carmen Martos, Raquel Negrao Carvalho
Publikováno v:
European Journal of Cancer
Introduction Europe is an important focus for compiling accurate and up-to-date world cancer statistics owing to its large share of the world's total cancer burden. This article presents incidence and mortality estimates for 25 major cancers across 4
Autor:
Che-Jui Lee, Michael G Leahy, Tomasz Switaj, Maria Debiec-Rychter, Sandra J. Strauss, Axelle Nzokirantevye, Anouk Neven, Bernd Kasper, Frank M. Speetjens, Antoine Italiano, Michaela Kubickova, Veit Bücklein, Raf Sciot, Agnieszka Wozniak, Jean-Yves Blay, Patrick Schöffski, Silvia Stacchiotti, Nicolas Isambert
Publikováno v:
European Journal of Cancer, 156, 12-23. ELSEVIER SCI LTD
Purpose: European Organisation for Research and Treatment of Cancer (EORTC) 90101 (CREATE) was a prospective, multicentric, non-randomised, open-label phase II bas-ket trial to assess the efficacy and safety of crizotinib in patients with different t
Autor:
Raphael J. Morscher, Pablo Berlanga, Caroline Brard, Ludovic Lacroix, Birgit Geoerger, Nicolas André, Souad Nebchi, Gaëlle Pierron, Nadège Corradini, Gilles Vassal, G Schleiermacher, Lynley V. Marshall, Peter G. Mortimer, Emilie De Carli, Xavier Paoletti, Isabelle Aerts, Jonathan Rubino
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩
European Journal of Cancer, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩
European Journal of Cancer, Elsevier, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩
European Journal of Cancer, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩
International audience; Aim: Arms E and F of the AcSé-ESMART phase I/II platform trial aimed to define the recommended dose and preliminary activity of the dual mTORC1/2 inhibitor vistusertib as monotherapy and with topotecan-temozolomide in a molec